Global Anti-Coccidial Drugs Market – Industry Trends and Forecast to 2030

Anti-Coccidial Drugs Market Analysis and Size

A major adoption of pet animals, which includes dogs, cats, and even horses, as companions of human beings has been witnessed during the recent years. The data stated by Kingsdale Animal Hospital in January 2022 showed that coccidia is one of the most common intestinal parasites found in dogs, and the occurrence of coccidia is 50 % in dogs, with a variation in incidence.

Data Bridge Market Research analyses a growth rate in the global anti-coccidial drugs market in the forecast period 2023-2030. The expected CAGR of the global anti-coccidial drugs market tends to be around 9.2% in the mentioned forecast period. The market was valued at USD 1,242.48 million in 2022 and would grow to USD 3,103.95 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Anti-Coccidial Drugs Market Scope and Segmentation

Market Definition

Coccidiosis is caused due to single-celled parasites (protozoa) called Eimeria, which undergo a simple gut life cycle. Any such drug which is used to combat the progression of coccidiosis in birds or animals, both non-food producing and food-producing, is known as an anticoccidial.  Its symptoms include weight loss, feces containing mucus or blood, dehydration, mild intermittent to severe diarrhea, and decreased breeding.

Global Anti-Coccidial Drugs Market Dynamics

Drivers

• Increasing share of animal ownership

Due to the promising economic condition, the highly developed economies represent a major large share of companion animal ownership. For instance, the Pet Food Manufacturers Association reported that in 2021, 17 million (59% of) households in the U.K. owned pets. These pet owners are more worried and aware of the safety of their pets. This creates an opportunity to diagnose fungal and bacterial diseases such as coccidiosis, which is an infection that is caused by the fungus coccidioides immitis among animals. This is projected to contribute to the overall market growth during the forecast period.  

• Rising expenditure on pet healthcare

Pet owners are investing in their pets hugely, such as in health insurance for pets, leading to rising expenditure on their health, thus acting as a major driver for market growth. For instance, according to the North American Pet Health Insurance Association (NAPHIA), around 4.41 million pets were insured in North America at the end of 2021. Furthermore, as per American Pet Products Association, USD 123.6 billion was spent on pets and animals in the U.S. in 2021, which augmented from about USD 99.0 billion in 2020. This expenditure by pet owners is likely to boost market growth over the forecast period.

Opportunities

• The growing burden of coccidiosis in target animals

The wide prevcalence of coccidiosis among the target animals of specific age demands the wide availability of the anticoccidial drugs. For instance, Eimeria is a genus of apicomplexan parasites, that includes several species capable of causing the disease coccidiosis in animals such as dogs, cattle, poultry, cats, and smaller ruminants such as sheep and goats. According to the research article "Coccidiosis of Cattle" published in August 2022, approximately 20 or more Eimeria species have been identified in cattle feces worldwide. Thus, this factor creates more opportunities for market growth.

• Increasing prevalence of isospora species

According to the Merck and Co. Inc. data updated in August 2022 on "Coccidiosis of Cats and Dogs", the isospora species is a common coccidiosis of cats and dogs. Approximately every cat gets infected by isospora felis in its lifetime. Moreover, as per the source mentioned above, coccidiosis usually occurs in young animals in facilities with potential contamination and  high population. Thus, this disease may become a problem in breeding or boarding catteries and kennels. This burden of coccidiosis among companion animals creates many different opportunities for developing anticoccidial drugs. This is projected to contribute to segment growth.

 Restraints/Challenges

• Limited studies and surveys

There are very limited studies and surveys that are hampering the growth of the market. Not many studies and awareness have been spread about this disease, and thus, this hampers the market's growth.

• High cost of drugs

The huge expenditure associated with anti-coccidial medications hampers the market growth. Different polyether antibiotics or ionophores, combination anti-coccidial drugs are of high cost which restricts the growth of the market.

This global anti-coccidial drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anti-coccidial drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Anti-Coccidial Drugs Market

The outbreak of COVID-19 showed an adverse impact on the global anti-coccidial drugs market . According to the article "The Initial Months of COVID-19: Dog Owners' Veterinary-Related Concerns," published in February 2021, dog owners feared that COVID-19 infection might lead to a decrease in disease diagnoses for pets. Moreover, the study showed that like many other professions, veterinarians were majorly impacted by the onset of COVID-19 in the initial phase of the pandemic. Thus, standard practices such as routine animal checkups, diagnoses, and surgeries were disturbed. These reduced services lowered the coccidiosis diagnosis, therefore, hampering the market growth.

But, in the post-pandemic era, poultry consumption and the adoption of companion animals increased. This led to a higher demand for diagnosis of poultry coccidiosis and companion animal coccidiosis. Thus, on the basis of above factors, the COVID-19 pandemic considerably impacted the market.

Recent Developments:

• In March 2022, Amlan International developed two new natural alternatives to antibiotics for poultry and livestock, such as Phylox Feed and NeutraPath. Phylox Feed is a natural alternative to anticoccidial drugs and vaccines, that can help producers to increase profitability.

Global Anti-Coccidial Drugs Market Scope

The global anti-coccidial drugs market is segmented on the basis of type, animals, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Synthetic Drugs
• Polyether Antibiotics or Ionophores
• Combination Anti-Coccidial Drugs
• Others

Animals

• Swine
• Fish
• Cattle
• Poultry
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Anti-Coccidial Drugs Market Regional Analysis/Insights

The global anti-coccidial drugs market is analysed and market size insights and trends are provided by type, animals, distribution channel and end-user as referenced above.

The major countries covered in the global anti-coccidial drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing positive growth for the global anticoccidial drugs market throughout the forecasted period due to increased healthcare and R&D expenditure and the presence of skilled professionals.

Asia-Pacific dominates the market due to increased poultry farming and increased awareness for anti-coccidial drugs through advertisement and media and rapidly improving healthcare infrastructure in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Anti-coccidial Drugs Market Share Analysis

The global anti-coccidial drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global anti-coccidial drugs market

Key players operating in the global anti-coccidial drugs market include:

• Impextraco NV (Belgium)
• Vetoquinol (France)
• Phibro Animal Health Corporation (U.S.)
• Huvepharma (Bulgaria)
• Virbac (France)
• Bayer AG (Germany)
• Merck & Co., Inc (U.S.),
• Novartis AG (Switzerland).
• Zoetis (U.S.)
• Elanco (U.S.)
• Ceva (France).
• ProBioGen AG (Germany)

SKU-56336